Lancet (London, England)AdultAgedFemaleHumansMale
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Lorenzo Falchi, Marcel Nijland, Huiqiang Huang, Kim M Linton, John F Seymour, Rong Tao, Michal Kwiatek, Abel Costa, Theodoros P Vassilakopoulos, Richard Greil, Ana Jiménez-Ubieto, Shane A Gangatharan, Ohad Benjamini, Catherine Thieblemont, Alessandra Tucci
Published: 202610.1016/S0140-6736(25)02360-8
Abstract
BACKGROUND: An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial…
Preview only. Read the full abstract at the source